Recent Updates
Recently added Catalysts
NBIX Positive Sentiment

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

Key Takeaway: Neurocrine Biosciences, Inc. announced its participation in several investor conferences in September 2026. The events include the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference 2026, and Morgan Stanley 24th Annual Global Healthcare Conference. Executives will engage in fireside chats, and webcasts will be available for those unable to attend live.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurocrine Biosciences is actively engaging with investors.
  • Participation in multiple high-profile healthcare conferences.
  • Showcases commitment to transparency through webcasts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
3.5%
average across 4 past catalysts
Lead asset
NBI-6024
Phase 1 · Type 1 Diabetes Mellitus

Full Press Release Details

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:
• Wells Fargo 21 st Annual Healthcare Conference. Fireside chat on Wednesday, September 9, 2026 at 12:45 PM ET in Boston
• Cantor Global Healthcare Conference 2026. Fireside chat on Thursday, September 10, 2026 at 8:35 AM ET in New York
• Morgan Stanley 24 th Annual Global Healthcare Conference. Fireside chat on Tuesday, September 15, 2026 at 10:45 AM ET in New York
The webcasts can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Contact: Neurocrine Biosciences, Inc. Tony Jewell (Media) 858-617-7578 [email protected]

Frequently Asked Questions

What conferences will Neurocrine Biosciences attend?

Neurocrine Biosciences will attend the Wells Fargo, Cantor Global, and Morgan Stanley conferences.

When is the Wells Fargo Healthcare Conference?

The Wells Fargo 21st Annual Healthcare Conference is on September 9, 2026.

How can I access the conference webcasts?

Webcasts can be accessed on Neurocrine Biosciences' website under the Investors section.

What is the purpose of Neurocrine Biosciences?

Neurocrine aims to relieve suffering for people with neurological and psychiatric disorders.

Last updated: Sep 2, 2026